Therefore, the introduction of HER2-guided therapies can have a positive effect on the treatment of patients with breast and stomach/stomach cancer with HER2 (Scaltriti et al., 2007; Campone et al., 2019). Here, ERBB2 is linked to gastric neoplasm.